8-K: VSee Health to Restate Past Financial Statements

VSee Health, Inc. announced it will restate multiple prior financial statements due to a series of accounting errors, impacting reports from 2023 and 2024.

Summary

• VSee Health, Inc. (the Company) will restate its previously issued consolidated financial statements for VSee Lab, Inc. and VSee Health, Inc.
• The affected periods include the fiscal year ended December 31, 2023, and interim periods ended March 31, June 30, September 30, 2023, and March 31, June 30, and September 30, 2024.
• The decision to restate was made by management in consultation with the Board of Directors and Audit Committee on July 17, 2025, with additional statements added on August 22, 2025.
• The restatement is necessary due to 12 identified errors, including issues with sales and use taxes, revenue recognition cutoffs, accrued expenses from acquisitions (Digital Health Acquisition Corp. and iDoc Virtual Telehealth Solutions, Inc.), compensation obligations, commitment fee classification, non-controlling interest classification, accrued interest on convertible notes, option grant date fair value, acquired accounts receivable, and income tax balances.
• The aggregate effects of these errors will be detailed in the upcoming 2024 Form 10-K.
• Management concluded that material weaknesses exist in the Company's internal control over financial reporting, and disclosure controls and procedures were not effective.

Sentiment

Score: 2

Explanation: The filing indicates significant financial reporting issues, including multiple accounting errors and material weaknesses in internal controls, necessitating a restatement of past financial statements. This is a highly negative development for investor confidence and operational integrity.

Negatives

• Prior Annual Financial Statements (December 31, 2023) and Prior Interim Financial Statements (March 31, June 30, September 30, 2023, and March 31, June 30, September 30, 2024) can no longer be relied upon.
• The Company failed to identify and accrue for sales and use taxes on revenue-generating transactions.
• Incorrect cutoff of revenue transactions occurred across multiple quarters in 2023.
• Accrued expenses for Digital Health Acquisition Corp. and iDoc Virtual Telehealth Solutions, Inc. were incorrectly recognized at the Business Combination date (June 24, 2024).
• Compensation-related obligations of iDoc were incorrectly recognized at the Business Combination date.
• A commitment fee for an equity line of credit was incorrectly recognized as a deferred expense and accrued liability as of June 30, 2024.
• The acquisition of the remaining non-controlling interest of This American Doc, Inc. was incorrectly classified within equity at the Business Combination date.
• Accrued interest related to convertible note obligations was incorrectly recognized.
• Grant date fair value for certain options issued on June 24, 2024, was incorrectly recognized.
• Accounts receivable balances acquired from iDoc were incorrectly recognized and measured at the Business Combination Date.
• Income tax-related balances were incorrectly recognized at the Business Combination date and for periods ended June 30, 2024, and September 30, 2024.
• Material weaknesses exist in the Company's internal control over financial reporting.
• The Company's disclosure controls and procedures were not effective.

Risks

• The restatement of financial statements could lead to a loss of investor confidence.
• Material weaknesses in internal control over financial reporting indicate a higher risk of future financial misstatements.
• Ineffective disclosure controls and procedures could result in a failure to timely and accurately report material information.
• Potential for regulatory scrutiny or enforcement actions due to financial reporting errors.
• The aggregate effects of the errors, to be described in the 2024 Form 10-K, could be significant.

Future Outlook

The Company will restate the Prior Financial Statements in the 2024 Form 10-K, where the aggregate effects of the errors and details of material weaknesses in internal controls and ineffective disclosure controls will be further described.

Management Comments

• Management of the Company, in consultation with the Company’s Board of Directors (including the members of the Audit Committee thereof), concluded that the Prior Financial Statements (other than the March 31, 2023 and March 31, 2024 consolidated financial statements of VSee Lab) should no longer be relied upon due to the impact of the errors noted below and will be restated.
• Management of the Company concluded that the March 31, 2023 and March 31, 2024 consolidated financial statements of VSee Lab should no longer be relied upon due to the impact of the errors noted below and will be restated.
• The Company’s management has concluded that, in light of the misstatements described above, material weaknesses exist in the Company’s internal control over financial reporting and that the Company’s disclosure controls and procedures were not effective.

Industry Context

This announcement highlights the critical importance of robust internal controls and accurate financial reporting, a common challenge for companies, especially those undergoing business combinations or rapid growth in the telehealth sector. While specific to VSee Health, such restatements can impact investor confidence across the broader industry if perceived as systemic issues.

Corporate Governance

Stakeholder Impact

• Shareholders will face uncertainty regarding the accuracy of past financial performance, potential stock price volatility, and a loss of confidence in management and financial reporting.
• Investors will need to re-evaluate their investment thesis based on restated financials and the identified control weaknesses.
• Management faces increased scrutiny and the immediate task of remediating internal control deficiencies and ensuring accurate future reporting.
• Regulators (SEC) are likely to increase oversight and potentially initiate inquiries into the Company's financial reporting practices.
• Auditors, WithumSmith+Brown, PC, will be involved in the restatement process and will need to ensure the accuracy of the revised financials.

Next Steps

• The Company will restate the Prior Financial Statements in the 2024 Form 10-K.
• The 2024 Form 10-K will further describe the aggregate effects of the errors.
• The 2024 Form 10-K will describe in more detail the material weaknesses in internal control over financial reporting and the ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

The disclosure of multiple accounting errors leading to a restatement of financial statements for several periods, coupled with the identification of material weaknesses in internal controls and ineffective disclosure procedures, signals significant operational and financial reporting risks. This erodes investor confidence and suggests a lack of reliability in the company's reported financial health. Until these issues are fully remediated and new, reliable financial statements are issued, the stock carries substantial downside risk, warranting a 'sell' recommendation for seasoned investors.

Keywords

VSee Health, VSEE, financial restatement, 8-K filing, accounting errors, internal controls, material weaknesses, SEC filing, telehealth, financial reporting, corporate governance